The Learned Intermediary Doctrine in Georgia
Published 8 authorities named
Under Georgia’s learned intermediary doctrine, the maker of a prescription drug or medical device owes its warning to the patient’s doctor, not to the patient. McCombs v. Synthes, 277 Ga. 252 (2003), says the manufacturer “has a duty to warn the patient’s doctor, who acts as a learned intermediary between the patient and the manufacturer”. So the claim doesn’t end. It moves to two questions: was the warning to the doctor adequate, and would a better one have changed what the doctor did?
Why it exists, and where it stops
Bryant v. Hoffmann-La Roche, 262 Ga. App. 401 (2003), explains that prescription drugs are available only through a physician who “has the power and responsibility to prescribe the drug only to those who would benefit”. That reasoning sets the doctrine’s limits.
| Situation | Treatment |
|---|---|
| Prescription drug | Doctrine applies, as in Presto |
| Prescription device or implant | Doctrine applies, as in McCombs |
| Warning that fails to reach the doctor adequately | Claim can proceed |
| Claim about the product's design | A separate question |
| Claim about a bad batch | A separate question |
| Consumer product with no doctor involved | Ordinary warning rules apply |
Failure to warn has the rules for ordinary products. The decisions on this page don’t address a claim built on advertising aimed at patients, off-label promotion, or a vaccine’s own federal rules. Other states have treated some of those differently, so have counsel look for current Georgia authority.
The two-step test
Dietz v. SmithKline Beecham, 598 F.3d 812 (11th Cir. 2010), applying Georgia law, lays out the sequence.
Step 1: adequacy. “If the warning was adequate, the inquiry ends, and the plaintiff cannot recover.” McCombs says the warnings must be “adequate or reasonable under the circumstances of the case”. For summary judgment, the trial court there “had to conclude” that the warning was adequate or reasonable as a matter of law. The case was reversed because the Court of Appeals refused to consider that point.
Step 2: causation. If the warning was inadequate, “the plaintiff must demonstrate that the deficient warning proximately caused the alleged injury”. In Dietz, the doctor said he would have prescribed Paxil even with the most current research and warnings. That “severs any potential chain of causation”.
So a plaintiff can lose even after proving the label was bad, depending on what the doctor says.
| What the doctor says | Effect |
|---|---|
| "I already knew of this risk." | Causation problem |
| "I didn't read the label." | A causation problem the defense will press |
| "I'd have prescribed it anyway." | Ended Dietz |
| "I'd have chosen differently, or watched for it." | Supports causation |
| "I'd have told the patient, who would have refused." | Needs support from the patient and the chart |
What adequacy has meant in the cases
In Bryant, an expert testified that the package insert was inadequate to warn physicians of the dangers of prescribing Posicor, especially with beta blockers, and “an issue remains as to whether the warnings Hoffmann-La Roche provided were sufficient under Georgia law”. That survived even though the expert also criticized the treating doctor’s decision.
Points to examine:
- Which label? The version in force when this prescription was written.
- What risk? A warning about one risk may not cover the risk that caused this harm.
- How strong? Its words, place in the label, and any rate it gives.
- What did the maker know? A danger known later triggers a duty under § 51-1-11(c), which keeps the duty to warn “once that danger becomes known”.
- Who received it? Package insert, letters to doctors, sales visits.
In Presto v. Sandoz Pharmaceuticals, 226 Ga. App. 547 (1997), the doctor had signed that he knew the package information, and nobody argued that the physician warning fell short. A general patient brochure didn’t create a duty to the family, because it didn’t claim to cover all dangers.
Other parties and theories
| Person | Claim | Note |
|---|---|---|
| The prescribing doctor | Malpractice or informed consent | Not a product claim, with its own rules |
| The pharmacist | Not the manufacturer | Robinson v. Williamson |
| The maker, on warranty | Weak without privity | Bryant, on the patient and the doctor's household |
| The maker, on design | Risk-utility with comment k | Bryant |
See pharmacy errors and pharmaceutical claims. Federal law sits on top. A generic drug’s label claim is preempted under PLIVA v. Mensing, and a device with premarket approval raises Riegel v. Medtronic. The doctrine matters for what remains, as federal preemption explains.
Building the record
- Get the chart first. It shows what the doctor considered, what was said, and what was prescribed.
- Depose the prescriber early. This testimony can decide causation, so prepare with the label and the literature.
- Have an expert on warnings. Bryant turned on such testimony. The gate is § 24-7-702.
- Collect the label history. Compare the versions before and after the event.
- Interview the patient. Would a warning have changed the decision?
Be careful about contact with a treating doctor, since rules on such contact and privacy apply. Ask counsel how to approach it. And don’t assume a doctor who’s also a defendant will speak freely.
The time limits are separate: two years in § 9-3-33, and ten years under § 51-1-11(b)(2), with exceptions for some negligence claims. A failure-to-warn claim gets different treatment in the repose exceptions.
Sources
- McCombs v. Synthes, 277 Ga. 252
- Bryant v. Hoffmann-La Roche, 262 Ga. App. 401
- Dietz v. SmithKline Beecham, 598 F.3d 812
- Presto v. Sandoz Pharmaceuticals, 226 Ga. App. 547
- Robinson v. Williamson, 245 Ga. App. 17
- Official Code of Georgia Annotated, November 2022 public release: §§ 9-3-33, 24-7-702, 51-1-11
This page was last reviewed in November 2026 for general information. Laws and court decisions can change after that date. It is not legal advice and does not create an attorney-client relationship.
Authorities cited
Georgia code
- O.C.G.A. § 51-1-11
- O.C.G.A. § 24-7-702
- O.C.G.A. § 9-3-33
Court decisions
- McCombs v. Synthes, 277 Ga. 252
- Bryant v. Hoffmann-La Roche, 262 Ga. App. 401
- Dietz v. SmithKline Beecham, 598 F.3d 812
- Presto v. Sandoz Pharmaceuticals, 226 Ga. App. 547
- Robinson v. Williamson, 245 Ga. App. 17
Leave a Reply